Gout News and Research RSS Feed - Gout News and Research

Gout is a type of arthritis that causes painful inflammation in the joints. Usually it affects one joint which is most commonly the big toe. However, it can affect any joint in the body such as the ankles, knees, wrists, elbows and any joints in the hands or finger.

Symptoms of gout usually develop rapidly and usually start at night. The joint may then start to feel normal again with any pain or discomfort eventually disappearing . However, most people who get gout will have further attacks in the future.

The symptoms of gout are caused by an above normal level of urate in the bloodstream, which builds up and forms crystals, mainly in and around joints and especially in the finger and toe joints. This can lead to intensely pain and inflammation.

There are several factors that can increase the level of blood urate. These include a diet rich in purines (which form urate when broken down) such as red meat, seafood and some other foods; excess alcohol consumption; the use of certain medicines such as diuretics; a family history of gout; kidney disease; and overweight or obesity.

Gout affects about 1% of the population and is more common in men, particularly those aged 30 to 60, and in women who have already experienced the menopause.
CT scans allow rheumatologists to diagnose gout

CT scans allow rheumatologists to diagnose gout

Gout is on the rise among U.S. men and women, and this piercingly painful and most common form of inflammatory arthritis is turning out to be more complicated than had been thought. [More]
Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Colchicine, a drug that's used to treat gout, has the beneficial side effect of lowering the risk of heart attack in patients taking it. Conversely, taxol, a drug for treating cancer, has the opposite effect; raising the risk of heart failure. [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]
Actavis files ANDA with FDA to market  Colchicine Tablets USP

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. [More]
Gouty tophi predict cardiovascular remodeling

Gouty tophi predict cardiovascular remodeling

Research shows that the severity of gout, rather than uric acid level, is significantly associated with changes in left ventricular diastolic function and left atrial volume. [More]

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout. [More]

Savient gets bankruptcy court approval to sell all assets to Crealta

Savient Pharmaceuticals, Inc. announced that it has received approval from the U.S. Bankruptcy Court for the District of Delaware to sell substantially all of the assets of Savient, including all KRYSTEXXA assets, to Crealta Pharmaceuticals LLC. [More]
Crealta to acquire all assets of Savient Pharmaceuticals

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. [More]

Researchers find evidence that gout clusters in families

It's historically known as 'the king of diseases and the disease of kings' and was long thought to be caused by an overindulgent lifestyle, but now scientists at The University of Nottingham have confirmed that 'gout' strongly runs in families. [More]
Implantable genetic circuit serves as early warning system for high blood-fat levels

Implantable genetic circuit serves as early warning system for high blood-fat levels

Humankind has a weight problem - and not only in the industrialised nations, either: the growing prosperity in many Asian or Latin American countries goes hand in hand with a way of life that quite literally has hefty consequences. [More]
3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). [More]
Study: Young fibromyalgia patients report worse symptoms, poorer quality of life than older patients

Study: Young fibromyalgia patients report worse symptoms, poorer quality of life than older patients

It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows. [More]

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows. [More]
Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect. [More]
Inflammation causally linked to functional decline in aging

Inflammation causally linked to functional decline in aging

Inflammation is the common denominator of many chronic age-related diseases such as arthritis, gout, Alzheimer's, and diabetes. But according to a Yale School of Medicine study, even in the absence of a disease, inflammation can lead to serious loss of function throughout the body, reducing healthspan - that portion of our lives spent relatively free of serious illness and disability. [More]

Gout increases risk of heart attack and stroke

New research published in this month’s Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke. [More]

Redd Remedies earns Better Nutrition Magazine's Best of Supplements Award for Gouch!

Redd Remedies, a leading provider of natural, condition-specific, health and wellness supplements, is this year's recipient of Better Nutrition Magazine's Best of Supplements Award with its all-natural, gluten-free Gouch!. [More]
Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years. [More]
DNA mutation 'signature' identified in urinary tract cancers linked to birthwort herb

DNA mutation 'signature' identified in urinary tract cancers linked to birthwort herb

Genomic sequencing experts at Johns Hopkins partnered with pharmacologists at Stony Brook University to reveal a striking mutational signature of upper urinary tract cancers caused by aristolochic acid, a plant compound contained in herbal remedies used for thousands of years to treat a variety of ailments such as arthritis, gout and inflammation. [More]
Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful. [More]